Successful Phase One Demonstrates Tumor Response With Increased Overall Survival for Lead VBL Therapeutics Compound in Cancer
5/16/2013 12:01:38 PM
More...
|
VBL Therapeutics Presents Positive Preclinical Data for VB-201 in Inflammatory Bowel Disease at Digestive Disease Week (DDW) 2012
5/21/2012 10:17:31 AM
More...
|
VBL Therapeutics Presents Positive Phase 2 Data for VB-201 in Psoriasis and Atherosclerosis at the Late-Breaking Abstract Session of the American Academy of Dermatology 70th Annual Meeting
3/19/2012 6:58:39 AM
More...
|
VBL Therapeutics to Present at the UBS Global Life Sciences Conference
9/13/2011 10:36:19 AM
More...
|
VBL Therapeutics To Present Updated Clinical Results for VB-111 at 2011 American Society of Clinical Oncology Annual Meeting
5/23/2011 8:38:39 AM
More...
|
VBL Therapeutics Presents Preclinical Data for VB-111 at the 14th Annual ASGCT Meeting
5/19/2011 10:31:02 AM
More...
|
VBL Therapeutics Presents Two Studies on VB-111 at 102nd Annual American Association for Cancer Research Meeting
4/6/2011 11:15:59 AM
More...
|
VBL Therapeutics Presents Two Studies on Novel Anti-Angiogenic Vector at 102nd Annual AACR Meeting
3/31/2011 9:29:36 AM
More...
|
VBL Therapeutics to Present at 10th Annual Needham Healthcare Conference
3/29/2011 10:13:59 AM
More...
|
VBL Therapeutics Announces Initiation of Two Clinical Trials for VB-111, Targeted, Dual-Action, Anti-Angiogenic, Vascular Disruptive Agent for Cancer
1/31/2011 11:20:21 AM
More...
|
|